A phase 2 trial of the FLT 3 inhibitor lestaurtinib ( CEP 701 ) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately one third of patients with acute myeloid leukemia (AML) and are associated with adverse prognosis. The important role played by FLT3 in the survival and proliferation of blasts, and its overexpression in most patients with AML, make FLT3 an attractive therapeutic target. We undertook a phase 2 trial of the FLT3selective tyrosine kinase inhibitor lestaurtinib (CEP701) used as monotherapy in untreated older patients with AML not considered fit for intensive chemotherapy, irrespective of FLT3 mutation status. Lestaurtinib was administered orally for 8 weeks, initially at a dose of 60 mg twice daily, escalating to 80 mg twice daily, and was generally well tolerated. Clinical activity, manifest as transient reductions in bone marrow and peripheral-blood blasts or longer periods of transfusion independence, was seen in 3 (60%) of 5 patients with mutated FLT3 and 5 (23%) of 22 evaluable wild-type FLT3 patients. Laboratory data demonstrated that clinical responses occurred where the presence of sustained FLT3-inhibitory drug levels were combined with in vitro cytotoxic sensitivity of blasts to lestaurtinib. Further evaluation of this compound, in combination with cytotoxic chemotherapy or other targeted agents, is warranted in both FLT3 mutant and wild-type patients. (Blood. 2006;108:3262-3270)

[1]  M. Levis,et al.  Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner , 2006, Leukemia.

[2]  K. Mills,et al.  Novel observation of three FLT3 codons mutated in tandem in an elderly acute myeloid leukaemia patient , 2006, British journal of haematology.

[3]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[4]  Kyu-Tae Kim,et al.  Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. , 2004, Blood.

[5]  K. Mills,et al.  CEP701 and PKC412 Predictably and Reliably Inhibit FLT3 Phosphorylation in Primary AML Blasts but Their Induction of a Cytotoxic Response Appears to Be Much More Variable. , 2004 .

[6]  B. Smith,et al.  In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. , 2004, Blood.

[7]  A. Stopeck,et al.  Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. , 2004, Leukemia research.

[8]  H. Kantarjian,et al.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. , 2004, Blood.

[9]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Cavalli,et al.  A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. , 2003, Blood.

[11]  M. Levis,et al.  FLT3: ITDoes matter in leukemia , 2003, Leukemia.

[12]  M. Heinrich,et al.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. , 2003, Blood.

[13]  Axel Benner,et al.  Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.

[14]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[15]  Donna Neuberg,et al.  CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). , 2002, Cancer cell.

[16]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[17]  B. Smith,et al.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. , 2002, Blood.

[18]  C. Sawyers.  Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. , 2002, Cancer cell.

[19]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[20]  J. Reilly,et al.  Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia , 2001, British journal of haematology.

[21]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[22]  W. Leonard,et al.  Essential Role of Signal Transducer and Activator of Transcription (Stat)5a but Not Stat5b for Flt3-Dependent Signaling , 2000, The Journal of experimental medicine.

[23]  B. Pulendran,et al.  Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. , 2000, Blood.

[24]  D. Birnbaum,et al.  SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor , 1999, Leukemia.

[25]  D. Birnbaum,et al.  FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates , 1998, Leukemia.

[26]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[27]  H. Drexler,et al.  Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. , 1996, Leukemia.

[28]  D. Birnbaum,et al.  Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. , 1996, Leukemia.

[29]  M. Borowitz,et al.  Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. , 1996, Blood.

[30]  S. Goff,et al.  Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. , 1995, Immunity.

[31]  D. Birnbaum,et al.  Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. , 1992, Blood.

[32]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[34]  M. Ratain,et al.  Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor , 2004, Investigational New Drugs.

[35]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[36]  D. Hicklin,et al.  FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. , 2004, Blood.

[37]  D. Gilliland,et al.  FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. , 2002, Blood.

[38]  山本 幸也,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies , 2002 .

[39]  T. Ley,et al.  PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[40]  I. Bernstein,et al.  Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. , 2001, Blood.